Tummarello D, Menichetti ET, Miseria S, et al. Advanced epithelial ovarian cancer: no difference in survival rate between exploratory laparotomy and inadequate debulking surgery as treatment approach before chemotherapy. J Chemother. 1990;2(4):260–3....
Background Survival rates for women diagnosed with ovarian cancer are much poorer than other gynaecological cancers and greatly depend on stage at diagnosis. A recent publication showed that unlike some other developed countries, there has been no improvement in the five‐year survival rate for those...
aOvarian cancer has one of the highest mortality rates of all gynecologic malignant tumors. More than 70% of patients are late-stage at diagnosis [1], and the 5-year survival rate is approximately 19~40% [2-3]. Locoregional recurrence and distant metastases are ominous events in patients wi...
Some studies have indicated that one of the major prognostic factors that affect the survival of patients with advanced ovarian cancer (AOC) is the residual tumor after primary cytoreduction surgery (PDS)—specifically, for microscopic or < 1 cm residual tumor, survival was higher than for ...
Ninety-one patients with untreated epithelial ovarian cancer, stages III and IV, were treated according to a therapeutic protocol including cytoreductive surgery whenever possible, chemotherapy with CAP (cyclophosphamide, doxorubicin, and cisplatin) and second-look laparotomy for those patients achieving a ...
In Group B, similar response rates occurred with irradiation or irradiation plus mustard therapy, but the latter regimen induced more complete responses of greater duration with doubling of the MST. These findings suggest that survival time in advanced ovarian cancer is inversely proportional to the ...
F. Tinquaut, G. Freyer, F. Chauvin, et al., Prognostic factors for overall survival in elder- ly patients with advanced ovarian cancer treated with chemotherapy: results of a pooled analysis of three GINECO phase II trials, Gynecol. Oncol. 143 (1) (2016) 22-26....
To improve the survival of advanced ovarian cancer patients, optimal cytoreductive surgery (e.g., maximum diameter of 1 cm or less for the largest residual tumor mass) followed by postoperative platinum/taxane combination chemotherapy are the cornerstones of treatment [3, 4]. The success rate ...
Maintenance Olaparib/Cediranib Fails to Extend PFS, OS in Ovarian Cancer Ashley Chan September 16th 2024 Article Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free and overall survival rates vs those given olaparib alone. ...
Finally, it was observed that two of the three control regions increased their utilization of neoadjuvant chemotherapy in 2013, which was later associated with a survival benefit. However, the authors note that the data were extracted from the National Cancer Database, which covers only 70% of ...